Abstract
Background and Aims : Attainment of low-density lipoprotein cholesterol (LDL-C) goals remains a challenge in patients with heterozygous familial hypercholesterolemia (FH). Combinations of lipid lowering medications (LLM) are commonly required. National registries play a crucial role to monitor quality of care in FH patients. We aimed to provide contemporary data on the number of used LLM, achieved lipid levels and attainment of LDL-C goals in FH patients from the Latvian Registry of FH (LRFH).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
